Hebei Medical University Fourth Hospital

This trial is testing a combination of local tumor removal and chemoradiotherapy (radiation plus capecitabine chemotherapy) in people with early-stage rectal cancer located low in the rectum. The goal is to see if this approach can effectively treat the cancer while avoiding the …

This phase II trial is testing whether combining precise, high-dose radiation (SABR) with the targeted drug axitinib and the immunotherapy toripalimab can shrink or control tumors in people with oligometastatic clear cell renal cell carcinoma—kidney cancer that has spread to five…

This trial is testing whether adding radiotherapy and immunotherapy to standard chemotherapy can shrink advanced colon tumors more effectively than chemotherapy alone. Adults with a specific type of stage T4M0 colon cancer will receive either the combination or chemotherapy only,…

This phase 2 trial tests whether adding radiotherapy to a combination of two drugs (QL1706 and bevacizumab) can shrink liver tumors that cannot currently be removed by surgery. The goal is to make enough tumors shrink so they can be surgically removed. The study will enroll 60 ad…

This study tests whether adding a drug called enlonstobart to short-course radiotherapy before surgery can improve outcomes for people with a specific type of advanced rectal cancer (pMMR). About 128 adults will be randomly assigned to receive either the standard treatment or the…

This trial tests whether a short course of focused radiation followed by chemotherapy (nab-paclitaxel and gemcitabine) plus the immunotherapy drug camrelizumab can shrink borderline or locally advanced pancreatic tumors enough to allow complete surgical removal. The study enrolls…

This study tests whether a combination of targeted drugs (pyrotinib and trastuzumab) plus chemotherapy can completely eliminate HER2-positive breast cancer before surgery. About 182 women with early-stage disease will receive 8 cycles of treatment. The main goal is to see if no c…

This Phase 2 trial tests whether adding entinostat to a two-drug regimen (dalpiciclib and letrozole) before surgery can better shrink tumors in women with HR-positive, HER2-negative early breast cancer. Sixty participants will receive either the three-drug combo or the standard t…

This study tests a drug called trilaciclib to protect bone marrow in people with solid tumors receiving chemotherapy. The goal is to reduce severe drops in blood cells, which can be dangerous and delay treatment. Researchers will build a model to predict who benefits most from th…

This study tests whether two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy can help people with advanced esophageal cancer that has come back or spread. About 25 adults will receive the treatment for up to 24 months. The goal is to see if the combination sh…

This study tests a combination of four drugs (iparomlimab, tuvonralimab, apatinib, and irinotecan) in 39 adults with advanced AFP-producing stomach or gastroesophageal junction cancer that has worsened after initial immunotherapy and chemotherapy. The goal is to see if this new m…

This study tests whether adding bevacizumab to standard chemotherapy before surgery can improve outcomes for people with early or locally advanced HER2-negative breast cancer. About 75 participants will receive the drug combination, and researchers will measure how many achieve a…

This phase II trial compares a daily pill (dalpiciclib) plus hormone therapy against standard chemotherapy for postmenopausal women with a specific type of breast cancer (ER+ HER2-). The goal is to see if the pill combination works as well as chemo but with fewer side effects. Ab…

This study tests whether the drug adebrelizumab can help prevent esophageal cancer from returning after surgery. About 142 adults who had their cancer completely removed will receive either adebrelizumab or a placebo. The main goal is to see how long patients stay cancer-free, an…

This study tests whether giving a single dose of radiation during breast-conserving surgery works as well as standard weeks-long radiation for early-stage, HER2-negative breast cancer. About 620 women aged 55 and older will take part. The goal is to see if this approach lowers th…

This phase 2 trial compares two chemotherapy combinations given before surgery for triple-negative breast cancer. About 520 women will receive either nab-paclitaxel plus carboplatin or nab-paclitaxel plus epirubicin. The goal is to see which combo better eliminates cancer cells i…

This study is testing a new oral drug called dalpiciclib in 420 people with hormone receptor-positive advanced breast cancer. Researchers are watching how well it works and what side effects occur in everyday medical practice, not a strict lab setting. The goal is to see if it ca…

This Phase 2 trial is testing two different chemotherapy combinations in 414 women with advanced triple-negative breast cancer (TNBC), a fast-growing type that lacks common treatment targets. One group gets nab-paclitaxel plus carboplatin, the other gets nab-paclitaxel plus capec…

This real-world study looks at whether a drug called mecapegfilgrastim can prevent neutropenia (a low white blood cell count) in cancer patients after chemotherapy, radiation, or immunotherapy. The study will follow 200 adults with solid tumors who are at high or moderate risk of…

This study watches for heart changes in 150 adults receiving chest radiation for lung, esophageal, breast, or thymus cancer. Researchers will check heart markers, electrical activity, and immune cells at the end of treatment and up to 3 months later. The goal is to find early sig…

This study enrolls 2000 cancer patients receiving immune checkpoint inhibitors. Researchers collect blood, urine, and stool samples before and after treatment to analyze genes, proteins, and other markers. The goal is to create a system that warns doctors early if a patient's org…